May 16, 2018
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, D.C. 20549
Re: | CESCA THERAPEUTICS INC. |
| Registration Statement on Form S-1 (Registration No. 333-224185) |
| Concurrence in Acceleration Request |
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Cesca Therapeutics Inc. that the effective date of the above-referenced registration statement be accelerated to 11:00 A.M. Eastern Time on Wednesday, May 16, 2018, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
| Very truly yours, | |
| H.C. WAINWRIGHT & CO., LLC | |
| By: /s/ Mark W. Viklund | |
| Name: Mark W. Viklund | |
| Title: Chief Executive Officer |
430 Park Avenue | New York, New York 10022 | 212.356.0500
Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC